ONC-392

Phase 2Small molecule

OOncoC4, Inc.

ONC-392 is one of 101 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsActive, not recruiting

Ovarian CancerActive, not recruiting

McrpcActive, not recruiting

Advanced Solid TumorsPreclinical

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

McrpcPhase 2

Active, not recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

10 2

Trodelvy

Gilead

Phase 2

1 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

5 4

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

3 5

PENPULIMAB KCQX

AAkeso

Phase 2

2 6

IL-2

FFate Therapeutics

Phase 2

7 7

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 8

JS207

SShanghai Junshi Bioscience Co., Ltd.

Phase 2

1 9

Ivarmacitinib

FFudan University

Phase 2

1 10

ZG006

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

Mcrpc

NCT05682443

Q4 2027

PreclinicalActive, not recruiting

Non-Small Cell Lung Cancer

NCT04140526

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting·OOncoC4, Inc.·Phase 2·NCT05446298·58 enrolled

mCRPC1 trial

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Active, not recruiting·OOncoC4, Inc.·Phase 1/2·NCT05682443·148 enrolled

Non-Small Cell Lung Cancer1 trial

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Active, not recruiting·OOncoC4, Inc.·Preclinical·NCT04140526·733 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ONC-392. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ONC-392 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ONC-392. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OncoC4, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOncoC4, Inc.

ONC-392

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Ovarian Cancer1 trial

mCRPC1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News